Family-owned Boehringer bucks pharma trend
This article was originally published in Scrip
Boehringer Ingelheim has reported impressive sales growth of 12% for 2012, to €14.7 billion. The expansion came as the global pharma industry grew by just 1.6%, down from 4.7% in 2011. "This confirms our strategy off organic growth, with our own R&D, thereby securing the long-lasting independence of Boehringer Ingelheim," said Professor Andreas Barner, chairman of the board of managing directors.
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.